Meeting
2015 Gastrointestinal Cancers Symposium
Folfoxiri with or without cetuximab as first-line treatment of patients with non-resectable liver, only metastatic colorectal cancer and KRAS/NRAS wild type (FOCULM study).
Authors
Yanhong Deng
Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Yanhong Deng , Lei Wang , Guanjian Liu , Huabin Hu , Yue Cai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02063529
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr TPS798)
DOI
10.1200/jco.2015.33.3_suppl.tps798
Abstract #
TPS798
Poster Bd #
F36
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
FOLFOXIRI with or without bevacizumab as first-line treatment for unresectable liver-only metastatic colorectal cancer patients with RAS mutation-type.
First Author: Yanhong Deng
Poster
2021 Gastrointestinal Cancers Symposium
Conversion from unresectable to resectable liver metastases in real-world patients with liver-only metastatic colorectal cancer (mCRC) treated with FOLFOXIRI plus bevacizumab: The Conversion trial.
First Author: Shahid Ahmed
Poster
2018 Gastrointestinal Cancers Symposium
Liver and/or lung metastasectomy after cetuximab or bevacizumab+FOLFIRI chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Sang-A Kim
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prediction of postoperative recurrence by integrating preoperative ctDNA levels and tumor metastasis volume in patients (pts) with colorectal cancer (CRC) with resectable lung or liver metastasis.
First Author: Hidekazu Oyoshi